CytomX Therapeutics (CTMX) Competitors $1.92 -0.07 (-3.27%) As of 11:14 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX vs. COGT, SNDX, JANX, SDGR, HROW, AMPH, NUVB, WVE, ETNB, and TLRYShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Cogent Biosciences (COGT), Syndax Pharmaceuticals (SNDX), Janux Therapeutics (JANX), Schrodinger (SDGR), Harrow (HROW), Amphastar Pharmaceuticals (AMPH), Nuvation Bio (NUVB), WAVE Life Sciences (WVE), 89BIO (ETNB), and Tilray Brands (TLRY). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Its Competitors Cogent Biosciences Syndax Pharmaceuticals Janux Therapeutics Schrodinger Harrow Amphastar Pharmaceuticals Nuvation Bio WAVE Life Sciences 89BIO Tilray Brands CytomX Therapeutics (NASDAQ:CTMX) and Cogent Biosciences (NASDAQ:COGT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment. Does the media prefer CTMX or COGT? In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 4 articles in the media. Cogent Biosciences' average media sentiment score of 1.47 beat CytomX Therapeutics' score of 1.25 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CTMX or COGT more profitable? CytomX Therapeutics has a net margin of 34.04% compared to Cogent Biosciences' net margin of 0.00%. CytomX Therapeutics' return on equity of 158.70% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics34.04% 158.70% 36.04% Cogent Biosciences N/A -223.82%-89.44% Which has stronger valuation & earnings, CTMX or COGT? CytomX Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$138.10M2.30$31.87M$0.563.44Cogent BiosciencesN/AN/A-$255.86M-$1.78-7.08 Do analysts recommend CTMX or COGT? CytomX Therapeutics currently has a consensus price target of $5.75, indicating a potential upside of 198.70%. Cogent Biosciences has a consensus price target of $20.00, indicating a potential upside of 58.67%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe CytomX Therapeutics is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.92 Do institutionals & insiders believe in CTMX or COGT? 67.8% of CytomX Therapeutics shares are held by institutional investors. 6.6% of CytomX Therapeutics shares are held by company insiders. Comparatively, 7.3% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, CTMX or COGT? CytomX Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. SummaryCytomX Therapeutics beats Cogent Biosciences on 11 of the 15 factors compared between the two stocks. Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$317.45M$3.11B$5.72B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio3.4421.2575.1226.29Price / Sales2.30431.74512.85173.43Price / Cash5.5344.4425.8129.90Price / Book-192.509.6413.646.29Net Income$31.87M-$53.18M$3.28B$270.21M7 Day Performance-7.89%0.39%0.16%1.79%1 Month Performance0.79%4.58%4.61%5.99%1 Year Performance59.09%10.13%78.04%27.88% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.1515 of 5 stars$1.93-3.3%$5.75+198.7%+61.8%$317.45M$138.10M3.44170News CoveragePositive NewsCOGTCogent Biosciences2.8915 of 5 stars$12.68-2.8%$20.00+57.7%+16.7%$1.49BN/A-7.1280Positive NewsGap UpSNDXSyndax Pharmaceuticals4.0255 of 5 stars$16.33-4.2%$38.89+138.1%-17.2%$1.47B$23.68M-4.20110Positive NewsJANXJanux Therapeutics3.1076 of 5 stars$24.81+3.5%$85.55+244.8%-52.9%$1.44B$10.59M-13.7830SDGRSchrodinger3.5406 of 5 stars$19.44+1.6%$27.83+43.2%-11.0%$1.41B$207.54M-7.84790Positive NewsHROWHarrow3.093 of 5 stars$39.77+7.5%$64.67+62.6%-5.1%$1.37B$199.61M-159.08180Positive NewsGap UpAMPHAmphastar Pharmaceuticals3.9794 of 5 stars$29.26-0.5%$31.60+8.0%-43.3%$1.37B$731.97M10.962,028Positive NewsNUVBNuvation Bio2.6547 of 5 stars$3.48-10.9%$7.50+115.8%+3.0%$1.33B$7.87M-5.5260Gap DownHigh Trading VolumeWVEWAVE Life Sciences4.3286 of 5 stars$7.58-8.6%$20.33+168.2%+18.9%$1.32B$108.30M-8.42240Positive NewsETNB89BIO2.6396 of 5 stars$8.57-3.4%$28.00+226.7%-5.4%$1.32BN/A-2.3740Positive NewsAnalyst ForecastTLRYTilray Brands3.0224 of 5 stars$1.12-5.9%$1.94+73.0%-32.2%$1.31B$821.31M-0.482,842Positive News Related Companies and Tools Related Companies Cogent Biosciences Competitors Syndax Pharmaceuticals Competitors Janux Therapeutics Competitors Schrodinger Competitors Harrow Competitors Amphastar Pharmaceuticals Competitors Nuvation Bio Competitors WAVE Life Sciences Competitors 89BIO Competitors Tilray Brands Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTMX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
